Screening of FDA-approved compounds using a Renilla luciferase–based PCA led to the discovery of 3 compounds that disrupted RAD54-BLM interaction at a nanomolar concentration range in cells and were effective in lowering the tumor load in preclinical mouse models. This evidence concerns the gene ATRX and neoplasm.